We acquire and advance proprietary drug candidates for underserved medical conditions with a focus on metabolic, pain/inflammation, and anti-aging therapeutic areas.
These medicines generally have at least one feature that makes them harder to “genericize” under traditional approach. As a consequence, these drugs can face less competition. We acquire and commercialize complex generic medicines for the US market.
Management team members has extensive networks with pharmaceutical and
biotech companies in North America, Europe and Asia.
NRDO (No Research Development Only) portfolio management company
Novel Medicines – acquisition, preclinical/clinical development, licensing deal
Complex Generics – acquisition, regulatory, commercialization in the US market